Premium
High‐dose versus low‐dose CMFP regimen in advanced breast cancer
Author(s) -
Kumar Anand,
Khan. N.,
Pant C. C.,
Khanna S.
Publication year - 1984
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930250417
Subject(s) - medicine , cyclophosphamide , regimen , breast cancer , prednisone , methotrexate , chemotherapy , oncology , toxicity , incidence (geometry) , cancer , physics , optics
Fifty cases of advanced breast cancer (stages III and IV) were treated by combination chemotherapy. The study compares the two different dose schedules and toxicities of a combination of cyclophosphamide, methotrexate, 5‐flurouracil, and prednisone. Results are better with high‐dose regimen, though the incidence of toxicity is much as compared to low‐dose schedules, but, considering the beneficial response, the high‐dose schedule is recommended.